Setting Up a Robust CGT Supply Chain (Part 2)

Today we continue our conversation with Mike Sweeney, Global Head of Strategy for Cell & Gene Therapies and Direct to Patient products at QuickSTAT Global Life Science Logistics, on how to set up a robust CGT supply chain. 

In Part 1, Mike described the explosion of cell and gene therapies registered for clinical trials – plus the hope and supply chain logistics challenges that growth provides. 

In Part 2, Mike discusses the benefits of advanced planning, the role of technology, as well as cold chain and chain of custody. We began, however, with his analysis of the ongoing regulatory change globally. I asked Mike: How does QuickSTAT stay on top of it, and what type of guidance do they give?